Evidence map›Paper›PMID 35368350›Full record

ArticleKidney3602021

Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19.

Minesh Khatri, David M Charytan, Sam Parnia, Christopher M Petrilli, Jeffrey Michael, David Liu, Vasishta Tatapudi, Simon Jones, Judith Benstein, Leora I Horwitz

Abstract read
In one paragraph

Article in Kidney360, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minesh KhatriNew York University Long Island School of Medicine, Mineola, New York.
David M CharytanDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
Sam ParniaDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
Christopher M PetrilliDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
Jeffrey MichaelDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
David LiuDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
Vasishta TatapudiDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
Simon JonesDepartment of Population Health, New York University Grossman School of Medicine, New York, New York.
Judith BensteinDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.
Leora I HorwitzDepartment of Medicine, New York University Grossman School of Medicine, New York, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with CKD ha ve impaired immunity, increased risk of infection-related mortality, and worsened COVID-19 outcomes. However, data comparing nondialysis CKD and ESKD are sparse. Methods: Patients with COVID-19 admitted to three hospitals in the New York area, between March 2 and August 27, 2020, were retrospectively studied using electronic health records. Patients were classified as those without CKD, those with nondialysis CKD, and those with ESKD, with outcomes including hospital mortality, ICU admission, and mortality rates. Results: Of 3905 patients, 588 (15%) had nondialysis CKD and 128 (3%) had ESKD. The nondialysis CKD and ESKD groups had a greater prevalence of comorbidities and higher admission D-dimer levels, whereas patients with ESKD had lower C-reactive protein levels at admission. ICU admission rates were similar across all three groups (23%-25%). The overall, unadjusted hospital mortality was 25%, and the mortality was 24% for those without CKD, 34% for those with nondialysis CKD, and 27% for those with ESKD. Among patients in the ICU, mortality was 56%, 64%, and 56%, respectively. Although patients with nondialysis CKD had higher odds of overall mortality versus those without CKD in univariate analysis (OR, 1.58; 95% CI, 1.31 to 1.91), this was no longer significant in fully adjusted models (OR, 1.11; 95% CI, 0.88 to 1.40). Also, ESKD status did not associate with a higher risk of mortality compared with non-CKD in adjusted analyses, but did have reduced mortality when compared with nondialysis CKD (OR, 0.57; 95% CI, 0.33 to 0.95). Mortality rates declined precipitously after the first 2 months of the pandemic, from 26% to 14%, which was reflected in all three subgroups. Conclusions: In a diverse cohort of patients with COVID-19, we observed higher crude mortality rates for patients with nondialysis CKD and, to a lesser extent, ESKD, which were not significant after risk adjustment. Moreover, patients with ESKD appear to have better outcom es than those with nondialysis CKD.

Indexed as

COVID-19Renal Insufficiency, ChronicComorbidityHospital MortalityHumansRetrospective Studieschronic kidney diseaseCKDCOVID-19dialysisend stage renal diseasemortalitySARS-CoV-2

Identifiers

PMID35368350
PMCPMC8786103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.